We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunoassays for Human Saliva Need Validation

By LabMedica International staff writers
Posted on 12 Mar 2012
Print article
Saliva has gained considerable attention as a possible alternate diagnostic fluid to blood because it is easily accessible and convenient to collect.

Commercial enzyme-linked immunosorbent assays (ELISAs) have proven to be a powerful tool for fast and reliable sample analysis, however few ELISAs have been validated for use with saliva, or their validation is often incomplete.

Scientists at Newcastle University (Newcastle upon Tyne, UK) collected from healthy volunteers 5-10 mL of saliva and gingival crevicular fluid (GCF) which is the primary source of inflammatory mediators in saliva. They analyzed and validated commercially available assays for 13 common biomarkers of inflammation and bone resorption, relevant for diseases such as rheumatoid arthritis and periodontitis.

The following ELISAs were assessed for their use with human saliva: C-reactive protein (CRP), hepatocyte growth factor (HGF), interleukin 1β (IL-1β), IL-6, matrix metalloproteinases -3 (MMP-3), MMP-8, MMP-9, Regulated on Activation cytokine (Rantes), tissue inhibitor of metalloproteinases-1 (TIMP-1) (Quantikine; R&D Systems, Abingdon, UK), albumin, hemoglobin (Bethyl Laboratories; Cambridge, UK), collagen telopeptides (Wampole Laboratories; Princeton, NJ, USA) and elastase (Hycult Biotech; Cambridge, UK).

A range of viscosity for the analyzed saliva samples was found which could be graded (subjectively) anywhere from very fluid to highly viscous. Various degrees of viscosity are mainly due to different amounts of large glycoproteins, such as mucins. Handling the highly viscous samples required special attention to pipetting techniques, and in some cases “reverse” pipetting instead of “forward” was considered to improve accuracy and to reduce pipetting errors.

Of all evaluated assays, only three, MMP-8, MMP-9, and TIMP-1 were recommended for use with saliva by the manufacturer. To fit within the range of each standard curve, most assays required a different sample dilution than that recommended for serum samples, which had to be determined empirically. A recovery between 80% and 120% is generally accepted as a good indication that the assay is suitable for use with the tested sample. With the exception of collagen telopeptides, recovery of the analyzed assays was within or very close to this range

The authors concluded that most ELISAs are suitable for analysis of saliva samples, even if this is not specifically recommended by the manufacturer. However, they believe that an independent validation of assays for saliva samples is important, as they have highlighted a number of cases in which validation and quality control analysis for some assays yielded questionable results when using saliva. The study was published in the March 2012 issue of the Journal of Immunological Methods.

Related Links:
Newcastle University
R&D Systems
Bethyl Laboratories

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.